Search clinical trials for: nerve growth factor

Total 169978 results

Zhangfa Song

Not yet recruiting

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

Metastatic Colorectal Cancer | MSS

China
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Maastricht University Medical Center
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

NSCLC Stage IV | Brain Metastases, Adult

Netherlands
Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Beijing Tiantan Hospital
Beijing University of Chemical Technology; Beijing Healthunion Cardio-Cerebrovascular...

Not yet recruiting

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis (NATURAL)

Amyotrophic Lateral Sclerosis
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Jin Lu, MD

Recruiting

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

Systemic Amyloidosis

China
Tri-Service General Hospital
Eusol Biotech Co., Ltd.

Not yet recruiting

The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome

Carpal Tunnel Syndrome
European Organisation for Research and Treatment...
Novartis

Not yet recruiting

177Lu-DOTATATE for Recurrent Meningioma (LUMEN-1)

Recurrent Meningioma
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Guangzhou Medical University

Not yet recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Leptomeningeal Metastasis
Kodiak Sciences Inc

Recruiting

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

Non-proliferative Diabetic Retinopathy

United States, Puerto Rico
Cairo University

Not yet recruiting

Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus

Lichen Simplex Chronicus

Egypt
Xuanwu Hospital, Beijing

Recruiting

The Therapeutic Effect of Thalidomide in Syringomyelia

Syringomyelia | Thalidomide

China
Henan Cancer Hospital

Recruiting

The Maintenance Treatment of "ITIVA" in AML Patients

Acute Myeloid Leukemia | Thalidomide | Maintenance Treatment | Minor Residue Disease | Interferon-α-1b | Interleukin-2 | Venentoclax | Azacitidine

China
Yonsei University

Not yet recruiting

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (ELPIS)

Non Small Cell Lung Cancer

Korea, Republic of
Dompé Farmaceutici S.p.A

Recruiting

A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease (REDUCO)

Dry Eye Disease

United States, Italy
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Second Affiliated Hospital, School of Medicine,...

Recruiting

Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia

Androgenetic Alopecia

China
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
Oncotherapeutics
Incyte Corporation

Not yet recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma
Chiang Mai University

Recruiting

Low-intensity Physical-cognitive Exercise and Cognitive Function

Mild Cognitive Impairment

Thailand
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
St. Joseph's Hospital and Medical Center, Phoenix
Texas Tech University

Not yet recruiting

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Cognitive Dysfunction | Neurodegenerative Disease, Hereditary | Cognitive Impairment, Mild | Amyloid Plaque | Inflammation, Brain
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Relapsed or Refractory Multiple Myeloma

Taiwan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent WHO Grade 4 Glioma

United States
AbbVie

Recruiting

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, Taiwan
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Spain, Canada, Finland, Argentina, Norway
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Starton Therapeutics, Inc

Recruiting

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
Jonsson Comprehensive Cancer Center
National Center for Advancing Translational Sciences (NCATS)

Recruiting

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Glioblastoma Multiforme | Epidermal Growth Factor Receptor | Glycolytic Index

United States
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
The First Hospital of Jilin University

Recruiting

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Acute Ischemic Stroke

China
Mayo Clinic

Recruiting

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

China
Massachusetts General Hospital
Sanofi; GlaxoSmithKline

Not yet recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Recruiting

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Multiple Myeloma | Aging | Relapse | Co-morbidity | Refractory

United States
Sohag University

Recruiting

Brain-derived Neurotrophic Factor (BDNF) Single Nucleotide Gene Polymorphism and Nerve Growth Factor as Risk Factors That Increase Severity of Allergic Rhinitis

Allergic Rhinitis

Egypt
The First Affiliated Hospital with Nanjing Medical...

Recruiting

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Multiple Myeloma

China
Sabine Mueller, MD, PhD
Washington University School of Medicine; Nationwide Children's Hospital; Rally...

Recruiting

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors (PNOC028)

Pediatric Brain Tumor | Recurrent Pediatric Brain Tumor | Pediatric Supratentorial Neoplasm

United States

3

Subscribe